Peter Sleight

Summary

Publications

  1. ncbi request reprint Arterial baroreflexes can determine long-term blood pressure. Baroreceptors and hypertension: time for a re-think?
    Peter Sleight
    John Radcliffe Hospital, University of Oxford, UK
    Exp Physiol 89:337-41. 2004
  2. ncbi request reprint Benefits, challenges, and registerability of the polypill
    Peter Sleight
    Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
    Eur Heart J 27:1651-6. 2006
  3. pmc Cardiovascular effects of music by entraining cardiovascular autonomic rhythms music therapy update: tailored to each person, or does one size fit all?
    P Sleight
    Cardiovascular Medicine, University of Oxford, Oxford, UK
    Neth Heart J 21:99-100. 2013
  4. ncbi request reprint The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension
    P Sleight
    Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, England
    Curr Cardiol Rep 3:511-8. 2001
  5. doi request reprint Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
    Peter Sleight
    CV Medicine, John Radcliffe Hospital, Oxford, UK
    J Hypertens 27:1360-9. 2009
  6. doi request reprint Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    J Hypertens Suppl 27:S23-9. 2009
  7. ncbi request reprint Angiotensin II and trials of cardiovascular outcomes
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, England, Oxford, UK
    Am J Cardiol 89:11A-16A; discussion 16A-17A. 2002
  8. ncbi request reprint Blood-pressure reduction and cardiovascular risk in HOPE study
    P Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
    Lancet 358:2130-1. 2001
  9. ncbi request reprint Where are clinical trials going? Society and clinical trials
    P Sleight
    University Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    J Intern Med 255:151-8. 2004
  10. pmc No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Medscape J Med 10:S6. 2008

Detail Information

Publications30

  1. ncbi request reprint Arterial baroreflexes can determine long-term blood pressure. Baroreceptors and hypertension: time for a re-think?
    Peter Sleight
    John Radcliffe Hospital, University of Oxford, UK
    Exp Physiol 89:337-41. 2004
  2. ncbi request reprint Benefits, challenges, and registerability of the polypill
    Peter Sleight
    Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK
    Eur Heart J 27:1651-6. 2006
    ..Discussions with regulatory bodies are required in order to obtain some 'balance' between an overcautious registration approach and the potentially large public health benefits that are likely to arise from the use of polypills...
  3. pmc Cardiovascular effects of music by entraining cardiovascular autonomic rhythms music therapy update: tailored to each person, or does one size fit all?
    P Sleight
    Cardiovascular Medicine, University of Oxford, Oxford, UK
    Neth Heart J 21:99-100. 2013
    ..These findings need to now be tested in the clinical setting since, if confirmed, this would greatly simplify the practical use of this promising tool...
  4. ncbi request reprint The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension
    P Sleight
    Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, England
    Curr Cardiol Rep 3:511-8. 2001
    ..Nevertheless, there is a strong case for an attack on the renin-angiotensin system. Whether this will be by ACE inhibition, angiotensin-II receptor blockade, or both, is the subject of current clinical trials...
  5. doi request reprint Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study
    Peter Sleight
    CV Medicine, John Radcliffe Hospital, Oxford, UK
    J Hypertens 27:1360-9. 2009
    ..We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)...
  6. doi request reprint Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    J Hypertens Suppl 27:S23-9. 2009
    ..Thus, telmisartan provides comparable efficacy to ramipril with less adverse events, which may encourage patient compliance...
  7. ncbi request reprint Angiotensin II and trials of cardiovascular outcomes
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, England, Oxford, UK
    Am J Cardiol 89:11A-16A; discussion 16A-17A. 2002
    ....
  8. ncbi request reprint Blood-pressure reduction and cardiovascular risk in HOPE study
    P Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, UK
    Lancet 358:2130-1. 2001
    ....
  9. ncbi request reprint Where are clinical trials going? Society and clinical trials
    P Sleight
    University Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
    J Intern Med 255:151-8. 2004
    ..These issues are best resolved by independent financial support (from government or other institutions) rather than relying on the commercial sponsor...
  10. pmc No HOPE without proof: do ARBs meet the standard for cardiovascular protection?
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Medscape J Med 10:S6. 2008
    ..The results of ONTARGET are anticipated to be available in 2008...
  11. ncbi request reprint Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis
    Sébastien Foulquier
    aCARIM, School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands bKlinik für Innere Medizin III, University Clinic of the Saarland, Homburg Saar cDepartment of Nephrology and Hypertension, University of Erlangen Nurnberg, Erlangen, Germany dCardiovascular Medicine, John Radcliffe Hospital, Oxford, UK ePopulation Health Research Institute, McMaster University, Hamilton, Ontario, Canada fBoehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany
    J Hypertens 32:1334-41. 2014
    ..We performed a post-hoc analysis to explore the hypothesis that telmisartan has a differential action in hypertensive vs. nonhypertensive patients...
  12. ncbi request reprint Current options in the management of coronary artery disease
    Peter Sleight
    Department of Cardiovascular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Am J Cardiol 92:4N-8N. 2003
    ..Current options for the management of CAD have their limitations, thus confirming the appropriateness of continuing the search for improved therapies to reverse the disease process and reduce the global burden...
  13. pmc The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
    Sarah Parish
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK
    Eur Heart J 30:2137-46. 2009
    ..The interdependence of these four risk factors is unclear...
  14. pmc The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
    Colin Baigent
    Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK
    Lancet 377:2181-92. 2011
    ..The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients...
  15. doi request reprint Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy
    Sripal Bangalore
    Division of Cardiovascular Medicine, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    Am Heart J 156:241-7. 2008
    ..The purpose of the study was to compare a beta-blocker-based strategy with a heart rate-lowering calcium antagonists-based strategy in patients with prior MI...
  16. ncbi request reprint Effect of long-term therapy with ramipril in high-risk women
    Eva Lonn
    Department of Medicine, Division of Cardiology and Population Health Institute, McMaster University, Hamilton, Ontario, Canada
    J Am Coll Cardiol 40:693-702. 2002
    ..We evaluated the effects of long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor ramipril on major cardiovascular (CV) outcomes in high-risk women...
  17. ncbi request reprint Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials
    Lutz Hilbrich
    Medical Science Department, Boehringer Ingelheim Pharma GmbH and Co KG, 55216 Ingelheim, Germany
    Eur Heart J 27:2158-64. 2006
    ..Megatrials are under threat from over-regulation, increasing costs, and difficulties in execution. These issues merit urgent public and political education and debate...
  18. ncbi request reprint Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial
    Gilles R Dagenais
    Laval University Heart and Lung Institute, Ste Foy, Quebec G1V 4G5, Canada
    Eur J Cardiovasc Prev Rehabil 12:75-81. 2005
    ..In recent large cardiovascular trials done in stable patients, 14-31% of the participants were smokers; the consequences of smoking in these trials using medications known to reduce cardiovascular events, have not been assessed...
  19. ncbi request reprint Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
    Koon Teo
    McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Am Heart J 148:52-61. 2004
    ..Currently, there is uncertainty about the role of ARBs when used alone or in combination with an ACE inhibitor in high-risk populations with controlled hypertension...
  20. doi request reprint Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  21. pmc Use of ramipril in preventing stroke: double blind randomised trial
    Jackie Bosch
    Canadian Cardiovascular Collaboration, McMaster University, 237 Barton St E, Hamilton, ON, Canada L8L 2X2
    BMJ 324:699-702. 2002
    ..To determine the effect of the angiotensin converting enzyme inhibitor ramipril on the secondary prevention of stroke...
  22. ncbi request reprint 1999 WHO/ISH Hypertension Guidelines--highlights & ESH update
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    J Hypertens 20:153-5. 2002
  23. ncbi request reprint Who is fooling us?
    Peter Sleight
    Lancet 360:873-4. 2002
  24. ncbi request reprint Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients
    Eva Lonn
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Eur J Cardiovasc Prev Rehabil 10:420-8. 2003
    ..The prognostic significance of left ventricular hypertrophy (LVH) identified by simple electrocardiographic (ECG) criteria in high-risk patients with established cardiovascular (CV) diseases is not clearly understood...
  25. pmc Preventing stroke with ramipril--authors' reply
    Salim Yusuf
    BMJ 326:52. 2003
  26. ncbi request reprint Predictors of adverse outcome among patients with hypertension and coronary artery disease
    Carl J Pepine
    Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610 0277, USA
    J Am Coll Cardiol 47:547-51. 2006
    ..We sought to determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD)...
  27. ncbi request reprint Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST)
    Issam Zineh
    Department of Pharmacy Practice, College of Pharmacy University of Florida, Gainesville, Florida 32610, USA
    Clin Cardiol 28:321-8. 2005
    ....
  28. ncbi request reprint Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial
    Henry R Black
    Rush Medical College of Rush University, Chicago, IL 60612, USA
    JAMA 289:2073-82. 2003
    ..Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial...
  29. ncbi request reprint Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
    Rory Collins
    Lancet 363:757-67. 2004
    ..Despite this observation, previous randomised trials had indicated that cholesterol-lowering statin therapy reduces the risk of stroke, but large-scale prospective confirmation has been needed...
  30. ncbi request reprint Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial
    Eva Lonn
    Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario
    JAMA 293:1338-47. 2005
    ..Experimental and epidemiological data suggest that vitamin E supplementation may prevent cancer and cardiovascular events. Clinical trials have generally failed to confirm benefits, possibly due to their relatively short duration...